Galenica Restructures Bichsel with Focus on Home Care Services

Galenica AG has announced a strategic shift for its subsidiary Bichsel, redirecting its focus towards home care services. Slated to cease pharmaceutical production by the end of 2026, this decision emerges due to the business's economic non-viability, affecting up to 170 positions. A consultation process has been initiated for impacted employees, with Galenica pledging support and a social plan to mitigate redundancies.

This transition aligns with Galenica's strategy of integrating healthcare and services. Bichsel, a long-standing player in clinical nutrition and pain therapy, will leverage its expertise alongside Lifestage Solutions to enhance home care offerings across Switzerland. Meanwhile, the transformation of "Grosse Apotheke Dr. G. Bichsel" into "Amavita Apotheke Bichsel Interlaken" will proceed from March 2026.

The discontinuation of production is expected to yield a one-off cost of CHF 35–40 million. However, it promises an annual improvement in Galenica’s adjusted EBIT by CHF 3 million post-closure. Bichsel has been integral to the Galenica network since 2019.